It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S. Food and Drug Administration, health practitioners may soon have access to three integrase strand transfer inhibitors to treat individuals living with HIV. Here, we review the use of raltegravir, elvitegravir, and dolutegravir for use in first- and second-line HIV treatment regimens and the issue of HIV resistance against integrase inhibitors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Jewish General Hospital, McGill University AIDS Centre, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000000094012774)
2 Jewish General Hospital, McGill University AIDS Centre, Lady Davis Institute for Medical Research, Montréal, Canada (GRID:grid.414980.0) (ISNI:0000000094012774); McGill University, Division of Experimental Medicine, Faculty of Medicine, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000000419368649); McGill University, Department of Microbiology and Immunology, Faculty of Medicine, Montréal, Canada (GRID:grid.14709.3b) (ISNI:0000000419368649)